CTRI/2021/03/032399尚未招募4 期
A Prospective, Open-Labeled, Multi-Center, Phase-IV Study to Evaluate the Safety and Clinical Acceptability of the Carivalan® the Single Pill Combination (SPC) of Carvedilol / Ivabradine in Indian Patients with Chronic Heart Failure and/or Chronic Coronary Syndrome
Serdia Pharmaceuticals India Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. 18 to 65 years old (both inclusive)
- •2. Patients receiving treatment for at least one of the following pathologies at the time of screening
- •a. chronic coronary syndrome (CCS) with stable angina
- •b. chronic heart failure (II-IV NYHA-class) with systolic dysfunction
- •c. coexisting chronic coronary syndrome (CCS) with stable angina and chronic heart failure (II-IV NYHA-class) with systolic dysfunction
- •3. Receiving ivabradine and carvedilol bid separately at stable dose as individual tablets concomitantly since >= 3 months and controlled for the given pathologies
- •4. Concurrently receiving standard care for stable chronic HF (as per recommendation 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF)
- •5. Sinus rhythm with resting HR >50 bpm as assessed automatically by a standard 12-lead ECG
- •6. No physical limitation to ingest and retain oral medication
- •7. Willingness to participate in the study and provide written informed consent
排除标准
- •1. Contraindication to use of Carivalan®
- •a. Patients hypersensitive to carvedilol, ivabradine or any of the other ingredients of this medicine, or to other beta blockers
- •2. Patients suffering from severe hepatic impairment
- •3. Concomitant use of Cytochrome p450 enzymes inducers (CYP3A4 inducer such as Rifampicin, Barbiturates, Phenytoin
- •4. History of recent acute MI, coronary revascularization, stroke, or transient ischemic attack <= 3 months), or with a transplanted heart, implanted pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy
- •5. Scheduled for coronary revascularization, or likely to require surgery for valvular disease during the study period
- •6. Permanent atrial fibrillation or flutter or any other cardiac arrhythmias which may interfere with function of sinoatrial node
- •7. Patients suffering from acute or unstable /decompensated heart failure
- •8. Patients suffering from unstable angina (a severe form of angina in which chest pain occurs very frequently, with or without exercise)
- •9. Sick sinus syndrome, sinoatrial block, congenital long QT or treated with QT prolonging medications, 2nd degree and complete atrioventricular block
- •10. Stroke or transient cerebral ischemia within previous <= 3 months prior at screening
- •11. Patients suffering from Prinzmetalâ??s angina (chest pain that occurs at rest and in cycles)
- •12. Patients suffering from a heart rhythm disorder, if your heart rate is too low (under 50 beats per minute) or if you feel weak, have decreased level of consciousness, shortness of breath, hypotension or chest pain (due to symptomatic or severe bradycardia)
- •13. Patients having a heart attack
- •14. Patients suffering from cardiogenic shock (a serious heart condition treated in hospitals and caused by very low blood pressure)
- •15. Patients heartbeat is exclusively regulated by pacemaker
- •16. Any cardiac condition which does not justify the inclusion of the patient in the study as per investigator discretion (e.g. severe primary valvular disease, active myocarditis, congenital heart disease, peripartum cardiomyopathy, etc.)
- •17. Patients having have a severe blood vessel disorder (for example Raynaudâ??s phenomenon)
- •18. Severe or uncontrolled hypertension (systolic BP [SBP] >= 190 mmHg or diastolic BP [DBP] >= 110 mmHg) uncontrolled hypotension (SBP <= 90 mmHg or DBP <= 50 mmHg)
- •19. Uncontrolled blood glucose levels (random/post-prandial >= 200 mg/dL, fasting >= 126 mg/dL)
- •20. Patients suffering from chronic obstructive pulmonary disease or COPD (lung disease with symptoms such as wheeziness, difficulty in breathing and chronic cough)
- •21. Patients having already experienced breathing problems such as asthma or bronchospasm (difficulty in breathing due to the narrowing of the airways)
- •22. Patients having metabolic acidosis
- •23. Patient with high blood pressure mostly due to renal condition like pheochromocytoma
- •24. Patients receiving:
- •a. medicines for treatment of fungal infections (such as ketoconazole, itraconazole)
- •b. antibiotics used for bacterial infections (such as clarithromycin, erythromycin given orally josamycin and telithromycin)
- •c. medicines called protease inhibitors used to treat HIV (such as nelfinavir, ritonavir)
- •d. nefazodone (medicine to treat depression)
- •e. diltiazem or
研究者
相似试验
进行中（未招募）
4 期
Clinical study to evaluate Safety and Efficacy of Adalimumab injection in patient with Ankylosing Spondylitis.CTRI/2023/11/059396Enzene Biosciences Ltd.
尚未招募
4 期
Clinical study to evaluate safety and efficacy of MyV3 Herbal Face care pack in patients to reduced Black spot, blemishes, pimples, scars and skin tan.CTRI/2024/05/067458MS Vee Herbal Care Pvt Ltd
进行中（未招募）
1 期
A trial to evaluate the safety and efficacy of oNKord® in participants with acute myeloid leukaemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantatioEUCTR2019-003686-17-NLGlycostem Therapeutics BV40
招募中
不适用
A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute myeloid leukemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantation.bone marrow cancer cells10024324leukemiaNL-OMON52744Glycostem Therapeutics8
尚未招募
4 期
A Single-Center, Prospective, Open Labeled, Phase IV Clinical Study to Evaluate Safety and Efficacy of MY V3 Immune Herbal Capsules in Healthy Participants.CTRI/2024/05/067457Sidhva Herbal and Foods Pondicherry